Access to and use of high blood pressure medications in brazil

Show simple item record

dc.contributor.author Mengue, Sotero Serrate
dc.contributor.author Bertoldi, Andrea Damaso
dc.contributor.author Ramos, Luiz Roberto [UNIFESP]
dc.contributor.author Farias, Mareni Rocha
dc.contributor.author Oliveira, Maria Auxiliadora
dc.contributor.author Leao Tavares, Noemia Urruth
dc.contributor.author Dourado Arrais, Paulo Sergio
dc.contributor.author Luiza, Vera Lucia
dc.contributor.author Dal Pizzol, Tatiane da Silva
dc.date.accessioned 2019-01-21T10:29:36Z
dc.date.available 2019-01-21T10:29:36Z
dc.date.issued 2016
dc.identifier http://dx.doi.org/10.1590/s1518-8787.2016050006154
dc.identifier.citation Revista De Saude Publica. Sao paulo, v. 50, n. 2, p. 8s, 2016.
dc.identifier.issn 0034-8910
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/49285
dc.description.abstract OBJECTIVE: To analyze the access to and use of medicines for high blood pressure among the Brazilian population according to social and demographic conditions. METHODS: Analysis of data from Pesquisa Nacional Sobre Acesso, Utilizacao e Promocao do Uso Racional de Medicamentos (PNAUM - National Survey on Access, Use and Promotion of Rational Use of Medicines), a nationwide cross-sectional, population-based study, with probability sampling, carried out between September 2013 and February 2014 in urban households in the five Brazilian regions. The study evaluated the access and use of medicines to treat people with high blood pressure. The independent variables were gender, age, socioeconomic status and Brazilian region. The study also described the most commonly used drugs and the percentage of people treated with one, two, three or more drugs. Point estimations and confidence intervals were calculated considering the sample weights and sample complex plan. RESULTS: Prevalence of high blood pressure was 23.7% (95% CI 22.8-24.6). Regarding people with this condition, 93.8% (95% CI 92.8-94.8) had indication for drug therapy and, of those, 94.6% (95% CI 93.5-95.5) were using the medication at the time of interview. Full access to medicines was 97.9% (95% CI 97.3-98.4) en
dc.description.abstract partial access, 1.9% (95% CI 1.4-2.4) en
dc.description.abstract and no access, 0.2% (95% CI 0.1-0.4). The medication used to treat high blood pressure, 56.0% (95% CI 52.6-59.2) were obtained from SUS (Brazilian Unified Health System), 16.0% (95% CI 14.3-17.9) from Popular Pharmacy Program, 25.7% (95% CI 23.4-28.2) were paid for by the patients themselves and 2.3% (95% CI 1.8-2.9) were obtained from other locations. The five most commonly used drugs were, in descending order, hydrochlorothiazide, losartan, captopril, enalapril and atenolol. Of the total number of patients on treatment, 36.1% (95% CI 34.1-37.1) were using two medicines and 13.5% (95% CI 12.3-14.9) used three or more. CONCLUSIONS: Access to medicines for the treatment of high blood pressure may be considered high and many of them are available free of charge. The most commonly used drugs are among those recommended as first-line treatment for high blood pressure control. The percentage of people using more than one drug seems to follow the behavior observed in other countries. en
dc.description.sponsorship Department of Pharmaceutical Services and Strategic Health Supplies (DAF) of the Secretariat of Science, Technology and Strategic Inputs - SCTIE of the Ministry of Health [25000.111834/2011-31]
dc.description.sponsorship Department of Science and Technology (DECIT) of the Secretariat of Science, Technology and Strategic Inputs - SCTIE of the Ministry of Health [25000.111834/2011-31]
dc.format.extent 8s
dc.language.iso eng
dc.publisher Elsevier Science Bv
dc.relation.ispartof Revista De Saude Publica
dc.rights Acesso aberto
dc.subject Noncommunicable Diseases en
dc.subject Hypertension en
dc.subject Prevalence en
dc.subject Adults en
dc.subject Drugs en
dc.title Access to and use of high blood pressure medications in brazil en
dc.title Acesso e uso de medicamentos para hipertensão arterial no Brasil pt
dc.type Artigo
dc.description.affiliation Programa de Pós-Graduação em Epidemiologia. Faculdade de Medicina. Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil
dc.description.affiliation Departamento de Medicina Social. Faculdade de Medicina. Universidade Federal de Pelotas. Pelotas, RS, Brasil
dc.description.affiliation Departamento de Medicina Preventiva. Escola Paulista de Medicina. Universidade Federal de São Paulo. São Paulo, SP, Brasil
dc.description.affiliation Departamento de Ciências Farmacêuticas. Centro de Ciências da Saúde. Universidade Federal de Santa Catarina. Florianópolis, SC, Brasil
dc.description.affiliation Departamento de Política de Medicamentos e Assistência Farmacêutica. Escola Nacional de Saúde Pública Sérgio Arouca. Fundação Oswaldo Cruz. Rio de Janeiro, RJ, Brasil
dc.description.affiliation Departamento de Farmácia. Faculdade de Ciências da Saúde. Universidade de Brasília. Brasília, DF, Brasil
dc.description.affiliation Departamento de Farmácia. Faculdade de Farmácia, Odontologia e Enfermagem. Universidade Federal do Ceará. Fortaleza, CE, Brasil
dc.description.affiliation Departamento de Produção e Controle de Medicamentos. Faculdade de Farmácia. Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil
dc.description.affiliationUnifesp Departamento de Medicina Preventiva. Escola Paulista de Medicina. Universidade Federal de São Paulo. São Paulo, SP, Brasil
dc.description.sponsorshipID SCTIE?MS: 25000.111834/2011-31
dc.identifier.file S0034-89102016000300305.pdf
dc.identifier.scielo S0034-89102016000300305
dc.identifier.doi 10.1590/S1518-8787.2016050006154
dc.description.source Web of Science
dc.identifier.wos WOS:000391447400009



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account